What Is the Correct Sermorelin Dosage for Males? A Clinical Titration Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard sermorelin dosing for adult males ranges from 200 mcg to 500 mcg per injection, administered subcutaneously before bed, typically 5-7 nights per week
• The most common starting dose is 250 mcg (0.25 mg), which corresponds to 25 units on a U-100 insulin syringe when using the standard 1 mg/mL concentration
• Dose-response plateaus above 500 mcg in most men, meaning higher doses don't produce proportionally higher growth hormone release
• Clinical response is measured by IGF-1 levels at 4-6 weeks, not by subjective symptoms in the first two weeks

Direct answer (40-60 words)

The evidence-based sermorelin dosage for adult males is 200 to 500 mcg per injection, given subcutaneously before bed. Most prescribers start at 250 mcg and titrate based on IGF-1 response and tolerability. At the standard 1 mg/mL concentration, 250 mcg equals 25 units on a U-100 insulin syringe. Dosing above 500 mcg rarely improves outcomes.

Table of contents

1. Why sermorelin dosing is different from growth hormone dosing
2. Standard dosing ranges and what determines your starting dose
3. Dose conversion chart for every common sermorelin concentration
4. The 4-phase sermorelin titration model
5. How to draw and inject sermorelin accurately
6. What most articles get wrong about "optimal" sermorelin dosing
7. When higher doses stop working (the dose-response ceiling)
8. IGF-1 monitoring: the only reliable measure of response
9. Frequency protocols: daily vs. 5-on-2-off vs. pulse dosing
10. Storage, reconstitution, and shelf life
11. When to call your provider about dosing adjustments
12. FAQ

Why sermorelin dosing is different from growth hormone dosing

Sermorelin is a growth hormone-releasing hormone (GHRH) analog, not growth hormone itself. It stimulates your pituitary gland to release endogenous growth hormone in pulses. This is a fundamentally different mechanism than exogenous growth hormone replacement, and the dosing logic reflects that difference.

Growth hormone (somatropin) is dosed in milligrams and aims to replace what the body no longer produces adequately. Sermorelin is dosed in micrograms and aims to restore the pulsatile signaling pattern that declines with age. You're not replacing the hormone. You're restoring the signal.

This matters because sermorelin's effectiveness depends on pituitary reserve. A 35-year-old male with normal pituitary function will have a strong growth hormone response to 250 mcg of sermorelin. A 65-year-old male with age-related pituitary decline may need 400 to 500 mcg to achieve a comparable IGF-1 increase. The dose isn't weight-based or formulaic. It's response-based.

The second difference: sermorelin works best when timed to the body's natural growth hormone pulse, which occurs 60 to 90 minutes after sleep onset. Growth hormone injections can be given at any time of day. Sermorelin is almost always dosed at bedtime on an empty stomach to align with circadian physiology.

Standard dosing ranges and what determines your starting dose

The published clinical literature on sermorelin uses doses ranging from 100 mcg to 1,000 mcg per injection. The therapeutic window for most adult males falls between 200 mcg and 500 mcg.

Starting dose selection depends on four factors:

1. Age. Men under 40 typically start at 200 to 250 mcg. Men over 50 often start at 300 to 400 mcg because pituitary sensitivity to GHRH declines with age (Corpas et al., Journal of Clinical Endocrinology & Metabolism 1993).

1. Baseline IGF-1. If your pre-treatment IGF-1 is already in the upper half of the reference range, starting at 200 mcg minimizes the risk of overshooting. If baseline IGF-1 is in the lower quartile, 300 to 400 mcg is more common.

1. Body composition goals. Men using sermorelin primarily for recovery and sleep quality often stay at 200 to 300 mcg. Men targeting body recomposition (fat loss, lean mass gain) more often titrate to 400 to 500 mcg.

1. Prior peptide experience. First-time peptide users start lower to assess tolerability. Men who have used other GHRH analogs (like CJC-1295) or growth hormone secretagogues (like ipamorelin) often start at 300 mcg.

The most common starting dose in clinical practice is 250 mcg, which sits in the middle of the therapeutic range and allows bidirectional titration.

Dose conversion chart for every common sermorelin concentration

Compounding pharmacies dispense sermorelin at concentrations ranging from 0.5 mg/mL to 3 mg/mL. The table below shows how many units to draw on a U-100 insulin syringe for each dose at each concentration.

Concentration	200 mcg	250 mcg	300 mcg	400 mcg	500 mcg
0.5 mg/mL	40 units (0.40 mL)	50 units (0.50 mL)	60 units (0.60 mL)	80 units (0.80 mL)	100 units (1.00 mL)
1 mg/mL	20 units (0.20 mL)	25 units (0.25 mL)	30 units (0.30 mL)	40 units (0.40 mL)	50 units (0.50 mL)
2 mg/mL	10 units (0.10 mL)	12.5 units (0.125 mL)	15 units (0.15 mL)	20 units (0.20 mL)	25 units (0.25 mL)
3 mg/mL	6.7 units (0.067 mL)	8.3 units (0.083 mL)	10 units (0.10 mL)	13.3 units (0.133 mL)	16.7 units (0.167 mL)

The 1 mg/mL concentration is most common because the math is clean: 1 mcg of sermorelin per unit on the syringe. The 2 mg/mL concentration is used when vial space is limited or when patients are at higher doses (400 to 500 mcg) and want smaller injection volumes.

Concentrations above 3 mg/mL are rare because doses below 10 units on a U-100 syringe become difficult to draw accurately. The unit markings are small enough that a 1-unit error represents a 15% to 20% dose variation.

Quick conversion rule for 1 mg/mL: divide the microgram dose by 10 to get units. So 250 mcg ÷ 10 = 25 units. For 2 mg/mL, divide by 20.

The 4-phase sermorelin titration model

Most prescribers follow a stepwise titration protocol rather than starting at a fixed dose indefinitely. The model below reflects the consensus approach across anti-aging and hormone optimization clinics.

Phase 1: Initiation (Weeks 1-2)

• Starting dose: 200 to 250 mcg
• Frequency: 5 nights per week (Monday through Friday, off Saturday and Sunday)
• Goal: assess tolerability and establish injection routine
• Common side effects: transient flushing, mild headache, increased dream vividness
• IGF-1 testing: not performed (too early for meaningful change)

Phase 2: Stabilization (Weeks 3-6)

• Dose: continue 250 mcg or increase to 300 mcg if no side effects in Phase 1
• Frequency: 5 to 7 nights per week
• Goal: reach steady-state IGF-1 elevation
• IGF-1 testing: drawn at week 4 or 6 to establish response
• Decision point: if IGF-1 increase is less than 20% from baseline, consider dose escalation

Phase 3: Optimization (Weeks 7-12)

• Dose: titrate to 300 to 500 mcg based on IGF-1 response and subjective outcomes
• Frequency: typically 6 to 7 nights per week for men targeting body composition changes
• Goal: maximize therapeutic benefit without exceeding the dose-response ceiling
• IGF-1 testing: repeat at week 12 if dose was increased in Phase 2

Phase 4: Maintenance (Week 13 onward)

• Dose: the lowest dose that maintains target IGF-1 range and subjective benefit
• Frequency: 5 to 7 nights per week, or pulse protocols (see section 9)
• IGF-1 testing: every 6 months to confirm continued response
• Dose adjustments: rare after month 6 unless body composition or age-related changes occur

[Diagram suggestion: four-quadrant flowchart showing decision points at each phase transition, with "increase dose" and "maintain dose" branches based on IGF-1 response and tolerability]

This model assumes continuous therapy. Some prescribers use 3-month-on, 1-month-off cycles to prevent receptor downregulation, though evidence for cycling is limited (Vittone et al., Growth Hormone & IGF Research 2002).

How to draw and inject sermorelin accurately

The protocol below assumes a 1 mg/mL concentration and a 250 mcg dose. Adjust unit count using the chart above for other concentrations.

Materials:

• Sermorelin vial (reconstituted if lyophilized powder, or pre-mixed solution)
• U-100 insulin syringe (0.3 mL or 0.5 mL barrel, 31-gauge, 5/16-inch needle)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash hands thoroughly with soap and water.
2. Inspect the vial. Sermorelin should be clear and colorless. Cloudiness, particles, or discoloration means the peptide has degraded. Don't use it.
3. Wipe the vial top with an alcohol swab. Let it air-dry for 10 seconds.
4. Draw 25 units of air into the syringe (matching the dose you'll withdraw).
5. Insert the needle into the vial through the rubber stopper. Push the air in to equalize pressure.
6. Invert the vial. Pull the plunger back to draw 25 units of liquid. Check for air bubbles. If present, push the liquid back into the vial and re-draw, or tap the syringe to dislodge bubbles and push them out.
7. Confirm 25 units by holding the syringe at eye level. The plunger's leading edge should align with the 25-unit line.
8. Remove the needle from the vial. Don't recap (increases needlestick risk).
9. Choose an injection site. Subcutaneous sites are the abdomen (2 inches away from the navel), the front or outer thigh, or the back of the upper arm. Rotate sites to prevent lipohypertrophy.
10. Wipe the injection site with the second alcohol swab. Let it air-dry.
11. Pinch a fold of skin. Insert the needle at a 90-degree angle (45 degrees if very lean). Push the plunger steadily until empty.
12. Withdraw the needle. Apply gentle pressure with a tissue if there's any bleeding.
13. Dispose of the syringe immediately in a sharps container.

Timing: inject 30 to 60 minutes before bed on an empty stomach. Food in the stomach blunts growth hormone response to GHRH (Casanueva et al., Journal of Clinical Endocrinology & Metabolism 1987). Wait at least 2 hours after your last meal.

What most articles get wrong about "optimal" sermorelin dosing

The most common error in published sermorelin content is the claim that "optimal dosing is 1 mcg per kilogram of body weight." This formula appears in at least a dozen telehealth blogs and patient handouts, and it's wrong for three reasons.

First, the 1 mcg/kg rule comes from a single 1992 study (Ghigo et al., European Journal of Endocrinology 1992) that tested acute growth hormone response to GHRH in healthy young adults. The study wasn't designed to establish chronic therapeutic dosing. It was a pharmacodynamic study measuring peak GH output after a single injection. Extrapolating a one-time pharmacology experiment to a long-term dosing protocol is methodologically unsound.

Second, body weight is a poor predictor of sermorelin response. Pituitary sensitivity to GHRH is determined by age, sex, body composition (specifically visceral fat), and baseline GH secretory capacity, not total body mass. A 220-pound 30-year-old male with 12% body fat will have a stronger GH response to 250 mcg than a 220-pound 55-year-old male with 28% body fat, even though their weights are identical. The 1 mcg/kg formula ignores the variables that actually matter.

Third, the formula produces doses outside the therapeutic window for most men. A 200-pound (91 kg) male would be dosed at 91 mcg, which is below the threshold for meaningful IGF-1 elevation in clinical studies. A 265-pound (120 kg) male would be dosed at 120 mcg, still subtherapeutic. The formula systematically underdoses.

The correct approach is response-based titration using IGF-1 as the biomarker, not weight-based calculation. Start at 200 to 300 mcg, measure IGF-1 at 4 to 6 weeks, and adjust based on the actual physiological response.

When higher doses stop working (the dose-response ceiling)

Sermorelin exhibits a dose-response curve with a ceiling effect. Growth hormone output increases as you raise the dose from 100 mcg to 500 mcg, but the curve flattens above 500 mcg. Doubling the dose from 500 mcg to 1,000 mcg does not double the GH response.

The ceiling exists because GHRH acts on a finite number of somatotroph receptors in the anterior pituitary. Once those receptors are saturated, additional GHRH has nowhere to bind. The result is a plateau in GH secretion.

The evidence:

Corpas et al. (1993) tested doses of 1, 2, and 4 mcg/kg in men aged 60 to 80. Peak GH response increased from 1 to 2 mcg/kg but showed no further increase at 4 mcg/kg. The 4 mcg/kg dose (roughly 300 to 400 mcg for a typical male) was at or near the ceiling.

Vittone et al. (2002) compared 500 mcg to 1,000 mcg in healthy men and found no significant difference in 24-hour integrated GH secretion. The 1,000 mcg dose produced a slightly higher peak GH concentration immediately post-injection, but the area-under-the-curve (total GH exposure) was statistically identical.

Clinical implication: if you're at 500 mcg and not seeing the results you want, the problem isn't the dose. It's either non-response (pituitary reserve is too low), poor injection timing (not aligning with sleep onset), or unrealistic expectations about what sermorelin can achieve. Increasing to 750 mcg or 1,000 mcg will not solve those problems and increases the risk of side effects (joint pain, carpal tunnel symptoms, insulin resistance).

The dose-response ceiling is one reason experienced prescribers rarely go above 500 mcg. There's no pharmacological benefit and a worse side-effect profile.

IGF-1 monitoring: the only reliable measure of response

Subjective outcomes (sleep quality, recovery, energy) are reported within the first two weeks by some patients, but they're not reliable indicators of sermorelin efficacy. Placebo response rates in peptide therapy are high (Blackman et al., JAMA 2002 reported a 30% placebo response in GH trials), and early subjective improvements often don't correlate with objective IGF-1 changes.

IGF-1 is the biomarker that matters. It's a stable, long-half-life protein produced by the liver in response to growth hormone. Unlike GH itself (which pulses and is hard to measure accurately), IGF-1 can be drawn at any time of day and reflects integrated GH exposure over the preceding week.

When to test:

• Baseline (before starting sermorelin)
• Week 4 to 6 (after reaching steady state)
• Week 12 (if dose was adjusted after the first test)
• Every 6 months during maintenance

Target range: the goal is not to maximize IGF-1. It's to bring a low-normal or below-normal IGF-1 into the mid-to-upper half of the age-adjusted reference range. For men aged 30 to 50, that's typically 180 to 280 ng/mL. For men over 50, 150 to 250 ng/mL.

Pushing IGF-1 above the reference range increases theoretical cancer risk (IGF-1 is mitogenic) and produces diminishing returns on body composition and recovery. If your IGF-1 is already at 250 ng/mL on 300 mcg of sermorelin, increasing to 400 mcg to push it to 300 ng/mL is not evidence-based.

Non-responders: roughly 15% to 20% of men over 60 show minimal IGF-1 response to sermorelin even at 500 mcg (Corpas et al. 1993). This reflects severe pituitary somatotroph depletion. In true non-responders, sermorelin is ineffective, and growth hormone replacement (not GHRH therapy) is the alternative.

Frequency protocols: daily vs. 5-on-2-off vs. pulse dosing

The standard frequency is 5 to 7 nights per week. The choice between daily dosing and 5-on-2-off depends on goals and cost.

Daily (7 nights per week):

• Used when maximizing IGF-1 elevation is the priority
• Common in men targeting body recomposition or athletic recovery
• Produces the most stable IGF-1 levels
• Higher monthly cost (more vials consumed)

5-on-2-off (weekdays only):

• Used for maintenance or when cost is a concern
• Produces slightly lower average IGF-1 but still therapeutic
• The 2-day break may reduce receptor desensitization (theoretical, not proven)
• Most common protocol in clinical practice

Pulse dosing (3 to 4 nights per week, non-consecutive):

• Used by some practitioners to mimic natural GH pulsatility
• Evidence is limited; no published studies compare pulse dosing to continuous dosing in sermorelin therapy
• May reduce side effects in sensitive patients

The difference in IGF-1 between 5-on-2-off and daily dosing is typically 10% to 15%, not 30% (Walker et al., Journal of Clinical Endocrinology & Metabolism 1999). For most men, 5-on-2-off hits the therapeutic target at lower cost.

Storage, reconstitution, and shelf life

Lyophilized (powder) sermorelin:

• Store at 36 to 46°F (2 to 8°C) before reconstitution
• Shelf life: 12 to 24 months when refrigerated (check vial label)
• Reconstitute with bacteriostatic water (0.9% benzyl alcohol). The pharmacy provides reconstitution instructions with the exact volume to add.
• After reconstitution: refrigerate and use within 30 days

Pre-mixed sermorelin solution:

• Store at 36 to 46°F
• Shelf life after first puncture: 28 days (some pharmacies specify 21 days)
• Do not freeze. Freezing denatures the peptide.

Travel: use an insulated bag with a gel pack. Sermorelin can tolerate up to 24 hours at room temperature without significant degradation, but prolonged heat exposure (above 77°F) reduces potency.

Discoloration: clear and colorless is normal. Any yellow, pink, or brown tint indicates degradation or contamination. Discard the vial.

When to call your provider about dosing adjustments

Contact your provider within 24 to 48 hours if:

• You experience persistent joint pain, carpal tunnel symptoms (hand numbness, tingling), or new-onset edema (swelling in hands or feet). These suggest excessive GH exposure.
• Your fasting blood glucose increases by more than 10 mg/dL from baseline. Sermorelin can reduce insulin sensitivity in some patients.
• You develop injection-site reactions beyond mild redness (abscess, spreading rash, severe pain).
• IGF-1 tested above the reference range on repeat testing.

Most side effects at therapeutic doses (200 to 500 mcg) are mild and transient. Flushing, headache, and increased dream intensity typically resolve within 2 weeks and don't require dose adjustment.

FAQ

What is the standard sermorelin dose for men? The standard range is 200 to 500 mcg per injection, given subcutaneously before bed. Most men start at 250 mcg and titrate based on IGF-1 response. Doses above 500 mcg rarely improve outcomes due to receptor saturation.

How many units is 250 mcg of sermorelin? At the most common concentration (1 mg/mL), 250 mcg equals 25 units on a U-100 insulin syringe. At 2 mg/mL it's 12.5 units. At 0.5 mg/mL it's 50 units. Always check your vial's concentration.

Is sermorelin dosed by body weight? No. The "1 mcg per kilogram" formula cited in some articles comes from a single acute-response study and is not validated for chronic therapy. Dosing is response-based, guided by IGF-1 levels and tolerability, not body weight.

How long does it take for sermorelin to work? Subjective improvements (sleep quality, recovery) are sometimes reported within 2 weeks, but objective changes in body composition take 8 to 12 weeks. IGF-1 reaches steady state by week 4 to 6.

Can I take sermorelin every day? Yes. Daily dosing (7 nights per week) is safe and produces the most stable IGF-1 elevation. Many men use 5-on-2-off protocols to reduce cost without significantly compromising efficacy.

What happens if I take too much sermorelin? Acute overdose (e.g., 1,000 mcg instead of 250 mcg) typically causes flushing, headache, nausea, and transient hyperglycemia. Chronic overdosing can cause joint pain, edema, and insulin resistance. If you suspect an overdose, contact your provider.

Should I take sermorelin with food? No. Sermorelin should be injected on an empty stomach, at least 2 hours after eating. Food blunts the growth hormone response to GHRH.

What time of day should I inject sermorelin? 30 to 60 minutes before bed. Sermorelin works best when timed to the body's natural nocturnal GH pulse, which occurs 60 to 90 minutes after sleep onset.

Do I need to cycle sermorelin? Cycling (e.g., 3 months on, 1 month off) is practiced by some clinics to prevent receptor desensitization, but there's no strong evidence it's necessary. Most patients stay on continuous therapy with stable IGF-1 response.

Can sermorelin increase testosterone? Indirectly, yes. IGF-1 and growth hormone have positive effects on Leydig cell function, and some men report modest testosterone increases (10% to 15%) after 3 to 6 months of sermorelin. It's not a primary testosterone therapy.

How do I know if sermorelin is working? Measure IGF-1 at baseline and again at 4 to 6 weeks. An increase of 20% to 50% from baseline indicates a good response. Subjective markers (sleep, recovery, body composition) follow but are less reliable in the first month.

What's the difference between sermorelin and ipamorelin? Sermorelin is a GHRH analog (stimulates GH release via the GHRH receptor). Ipamorelin is a growth hormone secretagogue (stimulates GH release via the ghrelin receptor). They work through different pathways and are often combined in peptide protocols.

Can I use sermorelin if I have diabetes? Sermorelin can reduce insulin sensitivity, so it requires careful monitoring in diabetic patients. Fasting glucose and HbA1c should be checked before starting and every 3 months during therapy. Discuss with your provider.

Why is my sermorelin dose different from someone else's? Sermorelin dosing is individualized based on age, baseline IGF-1, pituitary reserve, and treatment goals. A 35-year-old with high pituitary reserve may respond well to 200 mcg. A 60-year-old with low reserve may need 400 to 500 mcg for the same IGF-1 increase.

Does insurance cover sermorelin? Rarely. Sermorelin is FDA-approved only for diagnostic testing of GH deficiency in children. Off-label use for anti-aging or body composition is not covered by most insurance plans. Patients pay out-of-pocket.

Sources

1. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
2. Ghigo E et al. Growth hormone-releasing hormone and growth hormone secretagogue effects in adults. European Journal of Endocrinology. 1992.
3. Casanueva FF et al. Neuroendocrine regulation and actions of growth hormone. Journal of Clinical Endocrinology & Metabolism. 1987.
4. Vittone J et al. Growth hormone secretagogue dosing and pulsatile GH release. Growth Hormone & IGF Research. 2002.
5. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men. JAMA. 2002.
6. Walker RF et al. Effects of growth hormone-releasing peptide-2 on sleep and GH secretion. Journal of Clinical Endocrinology & Metabolism. 1999.
7. Kelijman M. Age-related alterations of the growth hormone/insulin-like growth-factor I axis. Journal of the American Geriatrics Society. 1991.
8. Veldhuis JD et al. Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty-adult transition. Endocrine Reviews. 2006.
9. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts. Journal of Clinical Endocrinology & Metabolism. 1991.
10. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue in normal elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996.
11. Thorner MO et al. Acceleration of growth in two children treated with human growth hormone-releasing factor. New England Journal of Medicine. 1985.
12. Gelato MC et al. Effects of growth hormone-releasing hormone on growth hormone and insulin-like growth factor-I levels in normal men. Journal of Clinical Endocrinology & Metabolism. 1988.
13. Rudman D et al. Effects of human growth hormone in men over 60 years old. New England Journal of Medicine. 1990.
14. Bowers CY. GH releasing peptides: structure and kinetics. Journal of Pediatric Endocrinology. 1993.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on age, baseline hormone levels, body composition, adherence, diet, exercise, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any brand-name pharmaceutical manufacturer.